The study aimed to understand how Colibactin-producing E. coli influences tumor heterogeneity, chemoresistance, and patient survival in right-sided CRC tumors. The main findings show that Colibactin-producing E. coli-infected tumors had high glycerophospholipid environments, reduced CD8+ T lymphocyte infiltration, and increased chemoresistance through lipid droplet accumulation and phosphatidylcholine remodeling. This evidence concerns the gene CD8A and colorectal carcinoma.